Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, shared an article on LinkedIn:
“Quick and insightful Commentary by Professor Carlo-Stella on our recent Blood paper on combining lymphoma immunotherapy with Standard of Care.”
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
Authors: Joshua D. Brody, et al.
